Cargando…

Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition

BACKGROUND: It is well established that parity and use of oral contraceptives reduce the risk of ovarian cancer, but the associations with other reproductive variables are less clear. METHODS: We examined the associations of oral contraceptive use and reproductive factors with ovarian cancer risk in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsilidis, K K, Allen, N E, Key, T J, Dossus, L, Lukanova, A, Bakken, K, Lund, E, Fournier, A, Overvad, K, Hansen, L, Tjønneland, A, Fedirko, V, Rinaldi, S, Romieu, I, Clavel-Chapelon, F, Engel, P, Kaaks, R, Schütze, M, Steffen, A, Bamia, C, Trichopoulou, A, Zylis, D, Masala, G, Pala, V, Galasso, R, Tumino, R, Sacerdote, C, Bueno-de-Mesquita, H B, van Duijnhoven, F J B, Braem, M G M, Onland-Moret, N C, Gram, I T, Rodríguez, L, Travier, N, Sánchez, M-J, Huerta, J M, Ardanaz, E, Larrañaga, N, Jirström, K, Manjer, J, Idahl, A, Ohlson, N, Khaw, K-T, Wareham, N, Mouw, T, Norat, T, Riboli, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241548/
https://www.ncbi.nlm.nih.gov/pubmed/21915124
http://dx.doi.org/10.1038/bjc.2011.371
_version_ 1782219527179730944
author Tsilidis, K K
Allen, N E
Key, T J
Dossus, L
Lukanova, A
Bakken, K
Lund, E
Fournier, A
Overvad, K
Hansen, L
Tjønneland, A
Fedirko, V
Rinaldi, S
Romieu, I
Clavel-Chapelon, F
Engel, P
Kaaks, R
Schütze, M
Steffen, A
Bamia, C
Trichopoulou, A
Zylis, D
Masala, G
Pala, V
Galasso, R
Tumino, R
Sacerdote, C
Bueno-de-Mesquita, H B
van Duijnhoven, F J B
Braem, M G M
Onland-Moret, N C
Gram, I T
Rodríguez, L
Travier, N
Sánchez, M-J
Huerta, J M
Ardanaz, E
Larrañaga, N
Jirström, K
Manjer, J
Idahl, A
Ohlson, N
Khaw, K-T
Wareham, N
Mouw, T
Norat, T
Riboli, E
author_facet Tsilidis, K K
Allen, N E
Key, T J
Dossus, L
Lukanova, A
Bakken, K
Lund, E
Fournier, A
Overvad, K
Hansen, L
Tjønneland, A
Fedirko, V
Rinaldi, S
Romieu, I
Clavel-Chapelon, F
Engel, P
Kaaks, R
Schütze, M
Steffen, A
Bamia, C
Trichopoulou, A
Zylis, D
Masala, G
Pala, V
Galasso, R
Tumino, R
Sacerdote, C
Bueno-de-Mesquita, H B
van Duijnhoven, F J B
Braem, M G M
Onland-Moret, N C
Gram, I T
Rodríguez, L
Travier, N
Sánchez, M-J
Huerta, J M
Ardanaz, E
Larrañaga, N
Jirström, K
Manjer, J
Idahl, A
Ohlson, N
Khaw, K-T
Wareham, N
Mouw, T
Norat, T
Riboli, E
author_sort Tsilidis, K K
collection PubMed
description BACKGROUND: It is well established that parity and use of oral contraceptives reduce the risk of ovarian cancer, but the associations with other reproductive variables are less clear. METHODS: We examined the associations of oral contraceptive use and reproductive factors with ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 327 396 eligible women, 878 developed ovarian cancer over an average of 9 years. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard models stratified by centre and age, and adjusted for smoking status, body mass index, unilateral ovariectomy, simple hysterectomy, menopausal hormone therapy, and mutually adjusted for age at menarche, age at menopause, number of full-term pregnancies and duration of oral contraceptive use. RESULTS: Women who used oral contraceptives for 10 or more years had a significant 45% (HR, 0.55; 95% CI, 0.41–0.75) lower risk compared with users of 1 year or less (P-trend, <0.01). Compared with nulliparous women, parous women had a 29% (HR, 0.71; 95% CI, 0.59–0.87) lower risk, with an 8% reduction in risk for each additional pregnancy. A high age at menopause was associated with a higher risk of ovarian cancer (>52 vs ⩽45 years: HR, 1.46; 95% CI, 1.06–1.99; P-trend, 0.02). Age at menarche, age at first full-term pregnancy, incomplete pregnancies and breastfeeding were not associated with risk. CONCLUSION: This study shows a strong protective association of oral contraceptives and parity with ovarian cancer risk, a higher risk with a late age at menopause, and no association with other reproductive factors.
format Online
Article
Text
id pubmed-3241548
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-32415482012-10-25 Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition Tsilidis, K K Allen, N E Key, T J Dossus, L Lukanova, A Bakken, K Lund, E Fournier, A Overvad, K Hansen, L Tjønneland, A Fedirko, V Rinaldi, S Romieu, I Clavel-Chapelon, F Engel, P Kaaks, R Schütze, M Steffen, A Bamia, C Trichopoulou, A Zylis, D Masala, G Pala, V Galasso, R Tumino, R Sacerdote, C Bueno-de-Mesquita, H B van Duijnhoven, F J B Braem, M G M Onland-Moret, N C Gram, I T Rodríguez, L Travier, N Sánchez, M-J Huerta, J M Ardanaz, E Larrañaga, N Jirström, K Manjer, J Idahl, A Ohlson, N Khaw, K-T Wareham, N Mouw, T Norat, T Riboli, E Br J Cancer Epidemiology BACKGROUND: It is well established that parity and use of oral contraceptives reduce the risk of ovarian cancer, but the associations with other reproductive variables are less clear. METHODS: We examined the associations of oral contraceptive use and reproductive factors with ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 327 396 eligible women, 878 developed ovarian cancer over an average of 9 years. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard models stratified by centre and age, and adjusted for smoking status, body mass index, unilateral ovariectomy, simple hysterectomy, menopausal hormone therapy, and mutually adjusted for age at menarche, age at menopause, number of full-term pregnancies and duration of oral contraceptive use. RESULTS: Women who used oral contraceptives for 10 or more years had a significant 45% (HR, 0.55; 95% CI, 0.41–0.75) lower risk compared with users of 1 year or less (P-trend, <0.01). Compared with nulliparous women, parous women had a 29% (HR, 0.71; 95% CI, 0.59–0.87) lower risk, with an 8% reduction in risk for each additional pregnancy. A high age at menopause was associated with a higher risk of ovarian cancer (>52 vs ⩽45 years: HR, 1.46; 95% CI, 1.06–1.99; P-trend, 0.02). Age at menarche, age at first full-term pregnancy, incomplete pregnancies and breastfeeding were not associated with risk. CONCLUSION: This study shows a strong protective association of oral contraceptives and parity with ovarian cancer risk, a higher risk with a late age at menopause, and no association with other reproductive factors. Nature Publishing Group 2011-10-25 2011-09-13 /pmc/articles/PMC3241548/ /pubmed/21915124 http://dx.doi.org/10.1038/bjc.2011.371 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Epidemiology
Tsilidis, K K
Allen, N E
Key, T J
Dossus, L
Lukanova, A
Bakken, K
Lund, E
Fournier, A
Overvad, K
Hansen, L
Tjønneland, A
Fedirko, V
Rinaldi, S
Romieu, I
Clavel-Chapelon, F
Engel, P
Kaaks, R
Schütze, M
Steffen, A
Bamia, C
Trichopoulou, A
Zylis, D
Masala, G
Pala, V
Galasso, R
Tumino, R
Sacerdote, C
Bueno-de-Mesquita, H B
van Duijnhoven, F J B
Braem, M G M
Onland-Moret, N C
Gram, I T
Rodríguez, L
Travier, N
Sánchez, M-J
Huerta, J M
Ardanaz, E
Larrañaga, N
Jirström, K
Manjer, J
Idahl, A
Ohlson, N
Khaw, K-T
Wareham, N
Mouw, T
Norat, T
Riboli, E
Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
title Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
title_full Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
title_fullStr Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
title_full_unstemmed Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
title_short Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
title_sort oral contraceptive use and reproductive factors and risk of ovarian cancer in the european prospective investigation into cancer and nutrition
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241548/
https://www.ncbi.nlm.nih.gov/pubmed/21915124
http://dx.doi.org/10.1038/bjc.2011.371
work_keys_str_mv AT tsilidiskk oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT allenne oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT keytj oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT dossusl oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT lukanovaa oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT bakkenk oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT lunde oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT fourniera oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT overvadk oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT hansenl oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT tjønnelanda oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT fedirkov oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT rinaldis oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT romieui oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT clavelchapelonf oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT engelp oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT kaaksr oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT schutzem oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT steffena oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT bamiac oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT trichopouloua oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT zylisd oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT masalag oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT palav oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT galassor oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT tuminor oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT sacerdotec oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT buenodemesquitahb oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT vanduijnhovenfjb oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT braemmgm oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT onlandmoretnc oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT gramit oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT rodriguezl oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT traviern oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT sanchezmj oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT huertajm oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT ardanaze oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT larranagan oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT jirstromk oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT manjerj oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT idahla oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT ohlsonn oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT khawkt oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT warehamn oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT mouwt oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT noratt oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition
AT ribolie oralcontraceptiveuseandreproductivefactorsandriskofovariancancerintheeuropeanprospectiveinvestigationintocancerandnutrition